0000049071-26-000050 | 10-Q | XBRL Viewer

Print Document

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Intangible Asset, Goodwill and Other [Abstract]
Amortization	$ 8	$ 15	$ 19	$ 30
Impairment of indefinite-lived intangible assets		$ 32	$ 0	$ 32	$ 128

- Definition

Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	6 Months Ended
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	Jun. 30, 2026
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Accounting Pronouncements Effective in Future Periods In November 2024, the FASB issued Accounting Standards Update No. 2024-03 — Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires significant additional disclosures disaggregating certain costs and expenses including purchases of inventory, employee compensation, depreciation, and intangible asset amortization. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2027 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our disclosures. In September 2025, The FASB issued Accounting Standards Update No. 2025-06 — Intangibles — Goodwill and Other — Internal Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The new guidance modernizes consideration of different methods of software development, updating the requirements for capitalization of software costs. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our interim 2028 financial statements, with early adoption permitted. We are currently evaluating the impact on our consolidated results of operations, financial position, and cash flows. There are no other recently issued accounting pronouncements that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480339/815-10-65-8

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480339/815-10-65-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479279/805-10-65-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org/250/tableOfContent

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

+ Details

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS	6 Months Ended
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS	Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS	BASIS OF PRESENTATION AND SIGNIFICANT EVENTS The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. This Form 10-Q should be read in conjunction with our audited Consolidated Financial Statements and Notes as of and for the year ended December 31, 2025 included in our 2025 Annual Report on Form 10-K that was filed with the Securities and Exchange Commission, or the SEC, on February 19, 2026. We refer to this Form 10-K as the “2025 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K. The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature. MaxHealth Acquisition On February 13, 2026, we acquired MaxHealth, a Florida-based primary care organization, for cash consideration of approximately $908 million, net of cash acquired. For additional information regarding acquisitions, refer to Note 3 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q. Value Creation Initiatives and Impairment Charges In order to create capacity to fund growth in our businesses, we committed to drive additional value for the enterprise through cost saving and productivity initiatives. In addition, in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions. As a result of these initiatives, we recorded charges of $56 million and $154 million for the three and six months ended June 30, 2026, respectively, and $29 million and $53 million for the three and six months ended June 30, 2025, respectively, within operating costs in the consolidated statements of income. The charges primarily relate to severance and associate exit costs, asset impairments, and external consulting expenses incurred to execute the program. We expect to incur additional charges over the course of the program. In addition, we recorded impairment charges related to minority-interest investments of $21 million within net investment income in our condensed consolidated statements of income for the three and six months ended June 30, 2026 and $32 million, relating to indefinite-lived intangible assets, within operating costs in our condensed consolidated statements of income for the three and six months ended June 30, 2025. Revenue Recognition Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that is recorded based upon established billing rates, less allowances for contractual adjustments, and is recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q. At June 30, 2026, accounts receivable related to services were $337 million. For the three and six months ended June 30, 2026, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet. For the three and six months ended June 30, 2026, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material. Reinsurance During 2025 and 2026, we entered into agreements with unrelated insurers that do not qualify for reinsurance accounting under GAAP, and are accounted for using deposit accounting. These contracts minimize the risk of catastrophic loss, reducing capital and surplus requirements. Total deposit assets and liabilities related to these reinsurance agreements that do not qualify for reinsurance accounting under GAAP are not material at June 30, 2026.

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Estimate of Amortization Expense (Details) $ in Millions	Jun. 30, 2026 USD ($)
Estimate of Amortization Expense
2026	$ 17
2027	28
2028	18
2029	16
2030	16
2031	$ 10

GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2026

Intangible Asset, Goodwill and Other [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for our reportable segments for the six months ended June 30, 2026 were as follows:


	Insurance		CenterWell		Total
	(in millions)
Balance at January 1, 2026	$	2,663	$	7,023	$	9,686
Acquisitions	246		585		831
Dispositions	—		(32)		(32)

Balance at June 30, 2026	$	2,909	$	7,576	$	10,485

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at June 30, 2026 and December 31, 2025:


	Weighted Average Life	June 30, 2026						December 31, 2025
		Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	790	$	—	$	790	$	790	$	—	$	790
Medicare licenses	Indefinite	262		—		262		262		—		262
Customer contracts/relationships	8.5 years	788		702		86		732		692		40
Trade names and technology	5.6 years	115		102		13		104		97		7
Provider contracts	11.9 years	66		64		2		67		65		2
Noncompetes and other	8.2 years	89		62		27		85		58		27

Total other intangible assets	8.4 years	$	2,110	$	930	$	1,180	$	2,040	$	912	$	1,128

For the three months ended June 30, 2026 and 2025, amortization expense for other intangible assets was approximately $8 million and $15 million, respectively. For the six months ended June 30, 2026 and 2025, amortization expense for other intangible assets was approximately $19 million and $30 million, respectively. We recorded an impairment charge of $128 million relating to our indefinite-lived intangible assets in 2025.

The following table presents our estimate of amortization expense remaining for 2026 and each of the next five succeeding years at June 30, 2026:


	(in millions)
For the years ending December 31,
2026	$	17
2027	28
2028	18
2029	16
2030	16
2031	10

For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

FAIR VALUE (Tables)

6 Months Ended

Jun. 30, 2026

Fair Value Disclosures [Abstract]

Schedule of Financial Assets Measured at Fair Value on Recurring Basis

The following table summarizes our fair value measurements at June 30, 2026 and December 31, 2025, respectively, for financial assets measured at fair value on a recurring basis:


	Fair Value Measurements Using
	Fair Value		Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
	(in millions)
June 30, 2026
Cash equivalents	$	5,557	$	5,557	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	2,506		—		2,506		—
Mortgage-backed securities	4,034		—		4,034		—
Tax-exempt municipal securities	408		—		408		—
Mortgage-backed securities:
Residential	404		—		404		—
Commercial	1,084		—		1,068		16
Asset-backed securities	1,092		—		937		155
Corporate debt securities	8,100		—		7,804		296
Total debt securities	17,628		—		17,161		467
Securities lending invested collateral	702		702		—		—
Total invested assets	$	23,887	$	6,259	$	17,161	$	467

December 31, 2025
Cash equivalents	$	3,945	$	3,945	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	2,278		—		2,278		—
Mortgage-backed securities	3,651		—		3,651		—
Tax-exempt municipal securities	428		—		428		—
Mortgage-backed securities:
Residential	388		—		388		—
Commercial	1,012		—		996		16
Asset-backed securities	783		—		656		127
Corporate debt securities	7,656		—		7,359		297
Total debt securities	16,196		—		15,756		440
Securities lending invested collateral	638		638		—		—
Total invested assets	$	20,779	$	4,583	$	15,756	$	440

Schedule of Changes in Fair Value of Assets Measured using Significant Unobservable Inputs (Level 3)

During the six months ended June

30, 2026 and 2025, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:


	For the six months ended June 30, 2026								For the six months ended June 30, 2025
	Mortgage-backed securities: Commercial		Asset-backed securities		Corporate debt securities		Total		Mortgage-backed securities: Commercial		Asset-backed securities		Corporate debt securities		Total
	(in millions)
Beginning balance at January 1	$	16	$	127	$	297	$	440	$	7	$	73	$	242	$	322
Total gains or losses:
Realized in earnings	—		—		(1)		(1)		—		—		—		—
Unrealized in other comprehensive income	—		(1)		(3)		(4)		—		—		3		3
Purchases	—		43		46		89		9		15		47		71
Maturities	—		—		(3)		(3)		—		—		(2)		(2)
Sales	—		—		(53)		(53)		—		—		—		—
Settlements	—		—		(1)		(1)		—		—		—		—
Transfers out	—		(14)		—		(14)		—		—		—		—
Transfers in	—		—		14		14		—		—		—		—
Balance at June 30	$	16	$	155	$	296	$	467	$	16	$	88	$	290	$	394

Schedule of Notional Amounts of Senior Notes Under Swap Agreements

The following table summarizes the notional amounts at June 30, 2026 and December 31, 2025, respectively, for our senior notes under the swap agreements:


	Notional amount at
Senior Notes Under Swap Agreements	June 30, 2026		December 31, 2025
	(in millions)
$1,500 million, 5.375% due April 15, 2031	$	700	$	700
$750 million, 5.875% due March 1, 2033	650		650
$850 million, 5.950% due March 15, 2034	800		800
$750 million, 5.550% due May 1, 2035	600		600
$250 million, 8.150% due June 15, 2038	200		—
$400 million, 4.625% due December 1, 2042	400		400
$750 million, 4.950% due October 1, 2044	750		600
$400 million, 4.800% due March 15, 2047	400		350
$500 million, 3.950% due August 15, 2049	500		450
$750 million, 5.500% due March 15, 2053	750		700
$1,000 million, 5.750% due April 15, 2054	1,000		800
$500 million, 6.000% due May 1, 2055	500		450
Total Senior Notes Under Swap Agreements	$	7,250	$	6,500

Schedule of Assumptions Used For Inputs In Fair Value Measurement

The table below presents the assumptions used for each reporting period.


	June 30, 2026		December 31, 2025
Annualized volatility	21.6% - 22.6%		18.9% - 19.9%
Credit spread	0.6% - 1.5%		1.1% - 1.6%
Revenue exit multiple	1.5x - 2.5x		1.5x - 2.5x
Weighted average cost of capital	10.0% - 14.0%		10.5% - 14.5%
Long term growth rate	3.0	%	3.0	%

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References + Details

DEBT (Tables)

6 Months Ended

Jun. 30, 2026

Debt Disclosure [Abstract]

Schedule of Carrying Value of Debt Outstanding

The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at June 30, 2026 and December 31, 2025:


	June 30, 2026		December 31, 2025
	(in millions)
Short-term debt:
Commercial paper	$	1,319	$	—

Senior notes:
$750 million, 1.350% due February 3, 2027	520		—
$600 million, 3.950% due March 15, 2027	429
Total senior notes	949		—
Total short-term debt	$	2,268	$	—
Long-term debt:
Senior notes:
$750 million, 1.350% due February 3, 2027	$	—	$	563
$600 million, 3.950% due March 15, 2027	—		466
$500 million, 5.750% due March 1, 2028	491		491
$500 million, 5.750% due December 1, 2028	497		497
$750 million, 3.700% due March 23, 2029	526		586
$500 million, 3.125% due August 15, 2029	338		388
$500 million, 4.875% due April 1, 2030	497		497
$1,500 million, 5.375% due April 15, 2031	1,479		1,493
$750 million, 2.150% due February 3, 2032	485		592
$750 million, 5.875% due March 1, 2033	737		750
$850 million, 5.950% due March 15, 2034	817		832
$750 million, 5.550% due May 1, 2035	735		746
$250 million, 8.150% due June 15, 2038	258		260
$400 million, 4.625% due December 1, 2042	368		374
$750 million, 4.950% due October 1, 2044	705		717
$400 million, 4.800% due March 15, 2047	390		396
$500 million, 3.950% due August 15, 2049	506		517
$750 million, 5.500% due March 15, 2053	712		727
$1,000 million, 5.750% due April 15, 2054	975		991
$500 million, 6.000% due May 1, 2055	477		486
Junior subordinated notes:
$1,000 million, 6.625% due September 15, 2056	986		—




Total long-term debt	$	11,979	$	12,369

FAIR VALUE - Schedule of Assumptions Used For Inputs In Fair Value Measurement (Details) - Level 3 Fair Value Measurement - Options	Jun. 30, 2026	Dec. 31, 2025
Long term growth rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.030	0.030
Minimum \| Annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.216	0.189
Minimum \| Credit spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.006	0.011
Minimum \| Revenue exit multiple
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	1.5	1.5
Minimum \| Weighted average cost of capital
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.100	0.105
Maximum \| Annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.226	0.199
Maximum \| Credit spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.015	0.016
Maximum \| Revenue exit multiple
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	2.5	2.5
Maximum \| Weighted average cost of capital
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.140	0.145

INVESTMENT SECURITIES - Narrative (Details) $ in Millions	6 Months Ended
INVESTMENT SECURITIES - Narrative (Details) $ in Millions	Jun. 30, 2026 USD ($) position	Dec. 31, 2025 USD ($)
Financing Receivable, Credit Quality Indicator [Line Items]
Minimum collateral as percentage of fair value of investment securities	102.00%
Fair value of collateral \| $	$ 702	$ 638
Non-cash securities lending, fair value \| $	$ 176	$ 193
Maximum individual state general bond obligation as a percentage of total debt securities (as percent)	1.00%
Securities in unrealized loss positions, number of positions \| position	2,075
Securities, number of positions \| position	2,925
S & P's, AA- rating
Financing Receivable, Credit Quality Indicator [Line Items]
Percentage of debt securities considered to be of investment-grade (as percent)	97.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-5

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 79
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-79

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-6A

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-15

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-15

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-15

Reference 24: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-15

Reference 25: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481962/310-10-50-29

+ Details

FAIR VALUE - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
FAIR VALUE - Narrative (Details) - USD ($)	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, fair value		$ 23,887,000,000		$ 20,779,000,000
Swap asset		17,000,000		57,000,000
Swap liability		146,000,000		51,000,000
Impairment of indefinite-lived intangible assets	$ 32,000,000	0	$ 32,000,000	128,000,000
Welsh Carson Anderson And Stowe \| Minimum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Call option strike price		1,000,000,000.0
Welsh Carson Anderson And Stowe \| Maximum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Call option strike price		1,600,000,000
Put Option
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial liability		1,600,000,000		1,400,000,000
Call Option
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial asset		20,000,000		13,000,000
Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial paper borrowings		1,319,000,000		0
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt outstanding		12,900,000,000		12,400,000,000
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt outstanding		12,700,000,000		12,200,000,000
Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cumulative, aggregate decrease to the carrying value of senior note		129,000,000
Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, fair value		$ 467,000,000		$ 440,000,000
Unobservable Inputs (Level 3) \| Investments \| Fair Value Risk
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Concentration risk (as percent)		2.00%		2.10%

INVESTMENT SECURITIES - Schedule of Gains (Losses) Related to Investment Securities Included Within Investment Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Investments, Debt and Equity Securities [Abstract]
Gross gains on investment securities	$ 8	$ 13	$ 10	$ 18
Gross losses on investment securities	(33)	(2)	(36)	(5)
Net recognized (losses) gains on investment securities	$ (25)	$ 11	$ (26)	$ 13

INVESTMENT SECURITIES - Schedule of Gross Unrealized Losses and Fair Value by Investment Category (Details) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Fair Value
Less than 12 months	$ 7,994	$ 2,331
12 months or more	7,370	8,740
Total	15,364	11,071
Gross Unrealized Losses
Less than 12 months	(126)	(16)
12 months or more	(863)	(851)
Total	(989)	(867)
U.S. Treasury and agency obligations
Fair Value
Less than 12 months	1,661	643
12 months or more	673	857
Total	2,334	1,500
Gross Unrealized Losses
Less than 12 months	(29)	(7)
12 months or more	(37)	(32)
Total	(66)	(39)
Mortgage-backed securities
Fair Value
Less than 12 months	1,746	593
12 months or more	1,907	2,373
Total	3,653	2,966
Gross Unrealized Losses
Less than 12 months	(33)	(3)
12 months or more	(343)	(333)
Total	(376)	(336)
Tax-exempt municipal securities
Fair Value
Less than 12 months	106	51
12 months or more	241	347
Total	347	398
Gross Unrealized Losses
Less than 12 months	(1)	0
12 months or more	(10)	(14)
Total	(11)	(14)
Residential
Fair Value
Less than 12 months	80	10
12 months or more	302	321
Total	382	331
Gross Unrealized Losses
Less than 12 months	(1)	0
12 months or more	(46)	(46)
Total	(47)	(46)
Commercial
Fair Value
Less than 12 months	301	77
12 months or more	685	794
Total	986	871
Gross Unrealized Losses
Less than 12 months	(3)	0
12 months or more	(45)	(47)
Total	(48)	(47)
Asset-backed securities
Fair Value
Less than 12 months	578	85
12 months or more	191	263
Total	769	348
Gross Unrealized Losses
Less than 12 months	(4)	0
12 months or more	(13)	(12)
Total	(17)	(12)
Corporate debt securities
Fair Value
Less than 12 months	3,522	872
12 months or more	3,371	3,785
Total	6,893	4,657
Gross Unrealized Losses
Less than 12 months	(55)	(6)
12 months or more	(369)	(367)
Total	$ (424)	$ (373)

ACQUISITIONS AND DIVESTITURES	6 Months Ended
ACQUISITIONS AND DIVESTITURES	Jun. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
ACQUISITIONS AND DIVESTITURES	ACQUISITIONS AND DIVESTITURES On February 13, 2026, we acquired MaxHealth, a leading primary care platform focused on providing high-quality, integrated care to adults and senior patients throughout Florida, for cash consideration of approximately $908 million, net of cash acquired. This resulted in a preliminary purchase price allocation to goodwill of approximately $800 million, other intangible assets of $71 million, and net tangible assets acquired of $59 million. The other intangible assets, which primarily consist of member relationships and trade names, have an estimated weighted average useful life of 6.9 years. The purchase price allocation is preliminary, subject to completion of valuation analysis, including for example, refining assumptions used to calculate the fair value of intangible assets. During 2026 and 2025, we acquired and disposed other health and wellness related businesses that, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition related costs recognized in 2026 and 2025 were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the quarter of acquisition, were not material for disclosure purposes.

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 13, 2026	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquisitions, net of cash acquired				$ 930	$ 1
Minority-interest investment impairment charges		$ 21		21
Impairment of indefinite-lived intangible assets			$ 32	0	32	$ 128
Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		337		337
Value Creation Initiatives
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restructuring and impairment charges		$ 56	$ 29	$ 154	$ 53
MaxHealth
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquisitions, net of cash acquired	$ 908

FAIR VALUE - Schedule of Changes in Fair Value of Assets Measured using Significant Unobservable Inputs (Level 3) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 440	$ 322
Total gains or losses:
Realized in earnings	(1)	0
Unrealized in other comprehensive income	(4)	3
Purchases	89	71
Maturities	(3)	(2)
Sales	(53)	0
Settlements	(1)	0
Transfers out	(14)	0
Transfers in	14	0
Ending balance	467	394
Mortgage-backed securities: Commercial
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	16	7
Total gains or losses:
Realized in earnings	0	0
Unrealized in other comprehensive income	0	0
Purchases	0	9
Maturities	0	0
Sales	0	0
Settlements	0	0
Transfers out	0	0
Transfers in	0	0
Ending balance	16	16
Asset-backed securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	127	73
Total gains or losses:
Realized in earnings	0	0
Unrealized in other comprehensive income	(1)	0
Purchases	43	15
Maturities	0	0
Sales	0	0
Settlements	0	0
Transfers out	(14)	0
Transfers in	0	0
Ending balance	155	88
Corporate debt securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	297	242
Total gains or losses:
Realized in earnings	(1)	0
Unrealized in other comprehensive income	(3)	3
Purchases	46	47
Maturities	(3)	(2)
Sales	(53)	0
Settlements	(1)	0
Transfers out	0	0
Transfers in	14	0
Ending balance	$ 296	$ 290

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Other Intangible Assets Included in Other Long-Term Assets (Details) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Other intangible assets:
Weighted Average Life (in years)	8 years 4 months 24 days
Total other intangible assets, Gross Carrying Amount	$ 2,110	$ 2,040
Amortizable intangible assets, Accumulated Amortization	930	912
Total other intangible assets, Net	1,180	1,128
Certificates of need
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	790	790
Medicare licenses
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 262	262
Customer contracts/relationships
Other intangible assets:
Weighted Average Life (in years)	8 years 6 months
Amortizable intangible assets, Gross Carrying Amount	$ 788	732
Amortizable intangible assets, Accumulated Amortization	702	692
Amortizable intangible assets, Net	$ 86	40
Trade names and technology
Other intangible assets:
Weighted Average Life (in years)	5 years 7 months 6 days
Amortizable intangible assets, Gross Carrying Amount	$ 115	104
Amortizable intangible assets, Accumulated Amortization	102	97
Amortizable intangible assets, Net	$ 13	7
Provider contracts
Other intangible assets:
Weighted Average Life (in years)	11 years 10 months 24 days
Amortizable intangible assets, Gross Carrying Amount	$ 66	67
Amortizable intangible assets, Accumulated Amortization	64	65
Amortizable intangible assets, Net	$ 2	2
Noncompetes and other
Other intangible assets:
Weighted Average Life (in years)	8 years 2 months 12 days
Amortizable intangible assets, Gross Carrying Amount	$ 89	85
Amortizable intangible assets, Accumulated Amortization	62	58
Amortizable intangible assets, Net	$ 27	$ 27

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2026

Equity [Abstract]

Schedule of Details of Dividend Payments

The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2026 under our Board approved quarterly cash dividend policy:


Record Date	Payment Date	Amount per Share		Total Amount
				(in millions)
2026 payments
12/26/2025	1/30/2026	$	0.8850	$	107
3/27/2026	4/24/2026	$	0.8850	$	106

SEGMENT INFORMATION - Schedule of Segment Results (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Segment Reporting [Line Items]
Premiums revenue	$ 38,834	$ 30,716	$ 76,543	$ 61,230
Services revenue	1,780	1,400	3,457	2,734
Total revenues	40,867	32,388	80,515	64,500
Net investment income	253	272	515	536
Operating expenses:
Benefits	35,370	27,565	69,077	54,100
Operating costs	3,978	3,547	8,002	6,927
Depreciation and amortization	159	178	322	361
Total operating expenses	39,507	31,290	77,401	61,388
Income from operations	1,360	1,098	3,114	3,112
External Revenues
Segment Reporting [Line Items]
Total revenues	40,614	32,116	80,000	63,964
Product
Segment Reporting [Line Items]
Premiums revenue	38,834	30,716	76,543	61,230
Service
Segment Reporting [Line Items]
Services revenue	1,780	1,400	3,457	2,734
Operating Segments \| Insurance
Segment Reporting [Line Items]
Total revenues	39,140	31,094	77,199	62,031
Net investment income	105	171	207	341
Operating expenses:
Benefits	35,423	27,621	69,121	54,296
Operating costs	2,758	2,558	5,542	5,092
Depreciation and amortization	139	149	281	303
Total operating expenses	38,320	30,328	74,944	59,691
Income from operations	820	766	2,255	2,340
Operating Segments \| CenterWell
Segment Reporting [Line Items]
Total revenues	6,790	5,537	12,890	10,632
Net investment income	0	0	0	0
Operating expenses:
Benefits	0	0	0	0
Operating costs	6,276	5,133	12,038	9,777
Depreciation and amortization	48	60	97	119
Total operating expenses	6,324	5,193	12,135	9,896
Income from operations	466	344	755	736
Operating Segments \| External Revenues \| Insurance
Segment Reporting [Line Items]
Total revenues	39,033	30,922	76,989	61,688
Operating Segments \| External Revenues \| CenterWell
Segment Reporting [Line Items]
Total revenues	1,581	1,194	3,009	2,276
Operating Segments \| Product \| Insurance
Segment Reporting [Line Items]
Premiums revenue	38,834	30,716	76,543	61,230
Operating Segments \| Product \| CenterWell
Segment Reporting [Line Items]
Premiums revenue	0	0	0	0
Operating Segments \| Service \| Insurance
Segment Reporting [Line Items]
Services revenue	199	206	446	458
Operating Segments \| Service \| CenterWell
Segment Reporting [Line Items]
Services revenue	1,581	1,194	3,009	2,276
Eliminations/ Corporate
Segment Reporting [Line Items]
Total revenues	(5,063)	(4,243)	(9,574)	(8,163)
Net investment income	148	101	308	195
Operating expenses:
Benefits	(53)	(56)	(44)	(196)
Operating costs	(5,056)	(4,144)	(9,578)	(7,942)
Depreciation and amortization	(28)	(31)	(56)	(61)
Total operating expenses	(5,137)	(4,231)	(9,678)	(8,199)
Income from operations	74	(12)	104	36
Eliminations/ Corporate \| External Revenues
Segment Reporting [Line Items]
Total revenues	0	0	2	0
Eliminations/ Corporate \| Product
Segment Reporting [Line Items]
Premiums revenue	0	0	0	0
Eliminations/ Corporate \| Service
Segment Reporting [Line Items]
Services revenue	0	0	2	0
Intersegment revenues
Segment Reporting [Line Items]
Total revenues	(5,211)	(4,344)	(9,884)	(8,358)
Intersegment revenues \| Insurance
Segment Reporting [Line Items]
Total revenues	2	1	3	2
Intersegment revenues \| CenterWell
Segment Reporting [Line Items]
Total revenues	$ 5,209	$ 4,343	$ 9,881	$ 8,356

INVESTMENT SECURITIES (Tables)

6 Months Ended

Jun. 30, 2026

Investments, Debt and Equity Securities [Abstract]

Schedule of Investment Securities Classified as Current and Long-Term

Investment securities classified as current and long-term were as follows at June 30, 2026 and December 31, 2025, respectively:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in millions)
June 30, 2026
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	2,572	$	—	$	(66)	$	2,506
Mortgage-backed securities	4,407		3		(376)		4,034
Tax-exempt municipal securities	419		—		(11)		408
Mortgage-backed securities:
Residential	451		—		(47)		404
Commercial	1,131		1		(48)		1,084
Asset-backed securities	1,107		2		(17)		1,092
Corporate debt securities	8,514		10		(424)		8,100
Total debt securities	$	18,601	$	16	$	(989)	$	17,628



December 31, 2025
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	2,314	$	3	$	(39)	$	2,278
Mortgage-backed securities	3,980		7		(336)		3,651
Tax-exempt municipal securities	442		—		(14)		428
Mortgage-backed securities:
Residential	434		—		(46)		388
Commercial	1,058		1		(47)		1,012
Asset-backed securities	791		4		(12)		783
Corporate debt securities	7,998		31		(373)		7,656
Total debt securities	$	17,017	$	46	$	(867)	$	16,196

Schedule of Gross Unrealized Losses and Fair Value by Investment Category

Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at June 30, 2026 and December 31, 2025, respectively:


	Less than 12 months				12 months or more				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
	(in millions)
June 30, 2026
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	1,661	$	(29)	$	673	$	(37)	$	2,334	$	(66)
Mortgage-backed securities	1,746		(33)		1,907		(343)		3,653		(376)
Tax-exempt municipal securities	106		(1)		241		(10)		347		(11)
Mortgage-backed securities:
Residential	80		(1)		302		(46)		382		(47)
Commercial	301		(3)		685		(45)		986		(48)
Asset-backed securities	578		(4)		191		(13)		769		(17)
Corporate debt securities	3,522		(55)		3,371		(369)		6,893		(424)
Total debt securities	$	7,994	$	(126)	$	7,370	$	(863)	$	15,364	$	(989)

December 31, 2025
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	643	$	(7)	$	857	$	(32)	$	1,500	$	(39)
Mortgage-backed securities	593		(3)		2,373		(333)		2,966		(336)
Tax-exempt municipal securities	51		—		347		(14)		398		(14)
Mortgage-backed securities:
Residential	10		—		321		(46)		331		(46)
Commercial	77		—		794		(47)		871		(47)
Asset-backed securities	85		—		263		(12)		348		(12)
Corporate debt securities	872		(6)		3,785		(367)		4,657		(373)
Total debt securities	$	2,331	$	(16)	$	8,740	$	(851)	$	11,071	$	(867)

Schedule of Gains (Losses) Related to Investment Securities Included Within Investment Income

The detail of gains (losses) related to investment securities and included within net investment income was as follows for the three and six months ended June 30, 2026 and 2025:


	Three months ended June 30,				Six months ended June 30,
	2026		2025		2026		2025
	(in millions)				(in millions)
Gross gains on investment securities	$	8	$	13	$	10	$	18
Gross losses on investment securities	(33)		(2)		(36)		(5)


Net recognized (losses) gains on investment securities	$	(25)	$	11	$	(26)	$	13

Schedule of Contractual Maturities of Debt Securities Available for Sale

The contractual maturities of debt securities available for sale at June 30, 2026, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.


	Amortized Cost		Fair Value
	(in millions)
Due within one year	$	1,134	$	1,127
Due after one year through five years	4,639		4,497
Due after five years through ten years	4,478		4,335
Due after ten years	1,254		1,055
Mortgage and asset-backed securities	7,096		6,614
Total debt securities	$	18,601	$	17,628

FAIR VALUE - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 5,557	$ 3,945
Total debt securities	17,628	16,196
Securities lending invested collateral	702	638
Total invested assets	23,887	20,779
U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	2,506	2,278
Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	4,034	3,651
Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	408	428
Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	404	388
Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,084	1,012
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,092	783
Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	8,100	7,656
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	5,557	3,945
Total debt securities	0	0
Securities lending invested collateral	702	638
Total invested assets	6,259	4,583
Quoted Prices in Active Markets (Level 1) \| U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Quoted Prices in Active Markets (Level 1) \| Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Quoted Prices in Active Markets (Level 1) \| Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Quoted Prices in Active Markets (Level 1) \| Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Quoted Prices in Active Markets (Level 1) \| Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Quoted Prices in Active Markets (Level 1) \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Quoted Prices in Active Markets (Level 1) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total debt securities	17,161	15,756
Securities lending invested collateral	0	0
Total invested assets	17,161	15,756
Other Observable Inputs (Level 2) \| U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	2,506	2,278
Other Observable Inputs (Level 2) \| Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	4,034	3,651
Other Observable Inputs (Level 2) \| Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	408	428
Other Observable Inputs (Level 2) \| Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	404	388
Other Observable Inputs (Level 2) \| Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,068	996
Other Observable Inputs (Level 2) \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	937	656
Other Observable Inputs (Level 2) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	7,804	7,359
Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total debt securities	467	440
Securities lending invested collateral	0	0
Total invested assets	467	440
Unobservable Inputs (Level 3) \| U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Unobservable Inputs (Level 3) \| Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Unobservable Inputs (Level 3) \| Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Unobservable Inputs (Level 3) \| Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Unobservable Inputs (Level 3) \| Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	16	16
Unobservable Inputs (Level 3) \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	155	127
Unobservable Inputs (Level 3) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	$ 296	$ 297

BENEFITS PAYABLE - Narrative (Details) - USD ($) $ in Billions	Jun. 30, 2026	Jun. 30, 2025
Insurance [Abstract]
Benefits payable including IBNR	$ 8.9	$ 7.0

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2026

Equity [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY

Dividends

The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2026 under our Board approved quarterly cash dividend policy:


Record Date	Payment Date	Amount per Share		Total Amount
				(in millions)
2026 payments
12/26/2025	1/30/2026	$	0.8850	$	107
3/27/2026	4/24/2026	$	0.8850	$	106

In April 2026, the Board declared a cash dividend of $0.885 per share payable on July 31, 2026 to stockholders of record as of the close of business on June 26, 2026. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.

Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. During the six months ended June 30, 2026, we repurchased 0.6 million shares in open market transactions for $103 million. These shares were repurchased at an average price of $182.13 under the February 2024 share repurchase authorization. During the six months ended June 30, 2025, we repurchased 0.4 million shares in open market transactions for $100 million. These shares were repurchased at an average price of $233.73 under the February 2024 share repurchase authorization.

Our remaining repurchase authorization was $2.7 billion as of July 28, 2026.

In connection with employee stock plans, we acquired 0.03 million common shares for $5 million and 0.04 million common shares for $9 million during the six months ended June 30, 2026 and 2025, respectively.

For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

MEDICARE PART D (Details) - USD ($) $ in Billions	Jun. 30, 2026	Dec. 31, 2025
Cms Subsidies Or Discounts
Product Information [Line Items]
Net assets	$ 1.1	$ 1.5
Cost Sharing Settlements Medicare Part D
Product Information [Line Items]
Net assets	$ 1.4	$ 1.6

DEBT - Commercial Paper and Other Short-Term Borrowings (Details) - USD ($)	6 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Commercial paper
Short-term Debt [Line Items]
Maximum amount outstanding during period	$ 2,630,000,000
Short-term debt outstanding	$ 1,319,000,000	$ 0
Short-term debt, weighted average interest rate, at point in time	4.04%
Federal Home Loan Bank Advances
Short-term Debt [Line Items]
Short-term debt outstanding	$ 0

- Definition

Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.

+ References + Details

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Tax Disclosure [Abstract]
Effective income tax rate (as percent)	25.60%	24.70%	25.20%	24.60%
Income taxes paid, net of refunds			$ 141	$ 29

DEBT - Pre-Capitalized Trust Security Arrangements (Details) $ in Millions	1 Months Ended
	May 31, 2026 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of trust preferred securities	$ 750
Financial instruments subject to mandatory redemption, settlement terms, maximum amount	750
Financial instruments subject to redemption, settlement terms, minimum consolidated net worth for exercise requirement	4,000
6.062% Senior Notes Due 2036 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750
Stated interest rate (as percent)	6.062%
Issuance right availability period (in years)	10 years
Financial instruments subject to redemption, settlement terms, semi-annual facility fees, percentage	1.661%
6.887% Senior Notes Due 2055 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750
Stated interest rate (as percent)	6.887%
Issuance right availability period (in years)	30 years
Financial instruments subject to redemption, settlement terms, semi-annual facility fees, percentage	1.916%

STOCKHOLDERS' EQUITY - Schedule of Details of Dividend Payments (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Jun. 30, 2026	Mar. 31, 2026
Equity [Abstract]
Amount per Share (in dollars per share)	$ 0.8850	$ 0.8850
Total Amount	$ 106	$ 107

EARNINGS PER COMMON SHARE COMPUTATION

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE COMPUTATION

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and six months ended June 30, 2026 and 2025:


	Three months ended June 30,				Six months ended June 30,
	2026		2025		2026		2025
	(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders	$	694	$	545	$	1,880	$	1,789
Weighted average outstanding shares of common stock used to compute basic earnings per common share	120,066		120,539		120,199		120,602
Dilutive effect of:
Employee stock options	—		—		—		—
Restricted stock	1,069		206		694		192
Shares used to compute diluted earnings per common share	121,135		120,745		120,893		120,794
Basic earnings per common share	$	5.78	$	4.52	$	15.64	$	14.83
Diluted earnings per common share	$	5.73	$	4.51	$	15.55	$	14.81
Number of antidilutive stock options and restricted stock excluded from computation	716		791		1,519		1,299

For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

Cover Page	6 Months Ended
Cover Page	Jun. 30, 2026 shares
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	1-5975
Entity Registrant Name	HUMANA INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	61-0647538
Entity Address, Address Line One	101 East Main Street
Entity Address, City or Town	Louisville
Entity Address, State or Province	KY
Entity Address, Postal Zip Code	40202
City Area Code	502
Local Phone Number	580-1000
Title of 12(b) Security	Common stock, $0.16 2/3 par value
Trading Symbol	HUM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	120,080,308
Entity Central Index Key	0000049071
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q2
Amendment Flag	false

BENEFITS PAYABLE - Schedule of Activity in Benefits Payable (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balances, beginning of period	$ 9,967	$ 10,440
Incurred related to:
Current year	69,519	54,738
Prior years	(442)	(638)
Total incurred	69,077	54,100
Paid related to:
Current year	(57,511)	(44,818)
Prior years	(8,657)	(8,662)
Total paid	(66,168)	(53,480)
Balances, end of period	$ 12,876	$ 11,060

DEBT

6 Months Ended

Jun. 30, 2026

Debt Disclosure [Abstract]

DEBT

The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at June 30, 2026 and December 31, 2025:


	June 30, 2026		December 31, 2025
	(in millions)
Short-term debt:
Commercial paper	$	1,319	$	—

Senior notes:
$750 million, 1.350% due February 3, 2027	520		—
$600 million, 3.950% due March 15, 2027	429
Total senior notes	949		—
Total short-term debt	$	2,268	$	—
Long-term debt:
Senior notes:
$750 million, 1.350% due February 3, 2027	$	—	$	563
$600 million, 3.950% due March 15, 2027	—		466
$500 million, 5.750% due March 1, 2028	491		491
$500 million, 5.750% due December 1, 2028	497		497
$750 million, 3.700% due March 23, 2029	526		586
$500 million, 3.125% due August 15, 2029	338		388
$500 million, 4.875% due April 1, 2030	497		497
$1,500 million, 5.375% due April 15, 2031	1,479		1,493
$750 million, 2.150% due February 3, 2032	485		592
$750 million, 5.875% due March 1, 2033	737		750
$850 million, 5.950% due March 15, 2034	817		832
$750 million, 5.550% due May 1, 2035	735		746
$250 million, 8.150% due June 15, 2038	258		260
$400 million, 4.625% due December 1, 2042	368		374
$750 million, 4.950% due October 1, 2044	705		717
$400 million, 4.800% due March 15, 2047	390		396
$500 million, 3.950% due August 15, 2049	506		517
$750 million, 5.500% due March 15, 2053	712		727
$1,000 million, 5.750% due April 15, 2054	975		991
$500 million, 6.000% due May 1, 2055	477		486
Junior subordinated notes:
$1,000 million, 6.625% due September 15, 2056	986		—




Total long-term debt	$	11,979	$	12,369

Junior Subordinated Notes

In March 2026, we issued $1.0 billion in aggregate principal amount of 6.625% fixed-to-fixed rate junior subordinated notes (Subordinated Notes) due September 15, 2056, which resulted in approximately $990 million of net proceeds after deducting underwriters' discounts and offering expenses. The Subordinated Notes will bear interest from, and including, March 9, 2026 to September 15, 2031 (First Reset Date) at a rate of 6.625% per year. The interest rate will reset every five years beginning on September 15, 2031, to equal the then-current-five-year U.S. Treasury rate plus a spread of 2.891%, provided the interest rate will not reset below 6.625%. We have the right

to defer payment of all or part of the current and accrued interest on the Subordinated Notes, on one or more occasions, for a period of up to 10 consecutive years. We may not, subject to certain limited exceptions, declare or pay any dividends or other distributions on, or redeem, repurchase or otherwise acquire any of our capital stock during the deferral period. We are currently not deferring payment. At our option, we may redeem some or all of the Subordinated Notes during specified periods and at specified redemption prices. We intend to use the net proceeds from this offering for general corporate purposes, including repayment of borrowings under our commercial paper program.

Senior Notes

In March 2026, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750 million aggregate principal amount of 1.350% senior notes maturing in February 2027, $600 million aggregate principal of 3.950% senior notes maturing in March 2027, $750 million aggregate principal amount of 3.700% senior notes maturing in March 2029, $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 and $750 million aggregate principal amount of 2.150% senior notes maturing in February 2032 during the period beginning on March 23, 2026 and ending on July 31, 2026. For the period ended June 30, 2026, we repurchased $44 million of the principal amount of the 1.350% senior notes maturing in February 2027 for approximately $43 million cash, $37 million of the principal amount of the 3.950% senior notes maturing in March 2027 for approximately $37 million cash, $61 million of the principal amount of the 3.700% senior notes maturing in March 2029 for approximately $59 million cash, $50 million of the principal amount of the 3.125% senior notes maturing in August 2029 for approximately $48 million cash and $108 million of the principal amount of the 2.150% senior notes maturing in February 2032 for approximately $94 million cash.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

Pre-Capitalized Trust Security Arrangements

In May 2026, we entered into Pre-Capitalized Trust Security arrangements (“P-Caps”) with Horseshoe Funding Trust I (“2036 Trust”) and Horseshoe Funding Trust II (“2055 Trust” and collectively, the “Trusts”). The Trusts each completed the issuance and sale of $750 million P-Caps exempted from registration under the Securities Act of 1933, as amended (the “Securities Act”). The P-Caps provide us with on-demand capital and liquidity by permitting us to issue up to $750 million aggregate principal amount of our 6.062% Senior Notes due 2036 (the “2036 Senior Notes”) to the 2036 Trust during a ten-year period and up to $750 million aggregate principal amount of our 6.887% Senior Notes due 2055 (the “2055 Senior Notes” and, together with the 2036 Senior Notes, the “Senior Notes”) to the 2055 Trust during a thirty-year period. Each Trust invested the proceeds from the sale of its P-Caps in principal and interest strips of U.S. Treasury securities (the “Eligible Assets”).

In May 2026, we also entered into separate facility agreements (each, a “Facility Agreement”) with each Trust and The Bank of New York Mellon Trust Company, N.A., as trustee for the Senior Notes (the “Trustee”). Under the Facility Agreements, each Trust granted the Company the right to require such Trust to purchase, on one or more occasions, up to $750 million aggregate principal amount of the applicable Senior Notes (each, an “Issuance Right”), and the Company agreed to pay semi-annual facility fees calculated at 1.661% per annum for the 2036 Trust and 1.916% per annum for the 2055 Trust on the unexercised portion of the applicable Issuance Right. We also entered into separate trust expense reimbursement agreements with each Trust.

An Issuance Right will be exercised automatically in full upon certain payment defaults under the applicable Facility Agreement or trust expense reimbursement agreement, or upon certain bankruptcy events. We will be required to exercise each Issuance Right in full upon certain other events, including if we reasonably believe our consolidated net worth has fallen below $4.0 billion, upon certain indenture defaults or change-of-control offer expiration events, or upon specified events relating to a Trust’s status under the Investment Company Act.

As of June 30, 2026, we had not exercised our Issuance Right under the P-Cap arrangements, and no senior notes had been issued to the Trusts. Accordingly, no debt related to the P-Cap arrangements has been recognized in the accompanying Condensed Consolidated Balance Sheets.

Revolving Credit Agreements

In May 2025, we entered into an amended and restated 5-year, $5.0 billion unsecured revolving credit agreement. The May 2025 revolving credit agreement (i) increases the amount of the commitments under our June 2023 revolving credit agreement from $2.642 billion to $5.0 billion and (ii) replaces our existing May 2024 364-day $2.1 billion unsecured revolving credit agreement, which expired in accordance with its terms.

Under the revolving credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.

The SOFR spread varies depending on our credit ratings ranging from 79.5 to 130.0 basis points. As of June 30, 2026, our SOFR was 101.5 basis points. We also pay an annual facility fee regardless of utilization. This facility fee varies depending on our credit ratings ranging from 8.0 to 20.0 basis points. As of June 30, 2026, our facility fee was 11.0 basis points.

The terms of our revolving credit agreement include standard provisions related to conditions of borrowing which could limit our ability to borrow additional funds. In addition, our credit agreement contains customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 42.7% as measured in accordance with the revolving credit agreement as of June 30, 2026. Upon our agreement with one or more financial institutions, we may expand the aggregate commitments under the revolving credit agreement by up to $1.0 billion, to a maximum of $6.0 billion.

As of June 30, 2026, we had $5.0 billion of remaining borrowing capacity under the credit agreement (which excludes the uncommitted $1.0 billion of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.

We have other customary relationships, including financial advisory and banking, with some parties to the revolving credit agreement.

For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

Commercial Paper

Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the six months ended June 30, 2026 was $2.63 billion, with $1.32 billion outstanding amount at June 30, 2026 and no

outstanding amount at December 31, 2025. The outstanding commercial paper at June 30, 2026 had a weighted average annual interest rate of 4.04%.

For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

Other Short-term Borrowings

We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At June 30, 2026 we had no outstanding short-term FHLB borrowings.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

EARNINGS PER COMMON SHARE COMPUTATION (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income available for common stockholders	$ 694	$ 545	$ 1,880	$ 1,789
Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares)	120,066	120,539	120,199	120,602
Shares used to compute diluted earnings per common share (in shares)	121,135	120,745	120,893	120,794
Basic earnings per common share (in dollars per share)	$ 5.78	$ 4.52	$ 15.64	$ 14.83
Diluted earnings per common share (in dollars per share)	$ 5.73	$ 4.51	$ 15.55	$ 14.81
Number of antidilutive stock options and restricted stock excluded from computation (in shares)	716	791	1,519	1,299
Employee stock options
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dilutive effect of employee stock options and restricted stock (in shares)	0	0	0	0
Restricted stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dilutive effect of employee stock options and restricted stock (in shares)	1,069	206	694	192

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)	6 Months Ended
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)	Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. This Form 10-Q should be read in conjunction with our audited Consolidated Financial Statements and Notes as of and for the year ended December 31, 2025 included in our 2025 Annual Report on Form 10-K that was filed with the Securities and Exchange Commission, or the SEC, on February 19, 2026. We refer to this Form 10-K as the “2025 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K. The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Max Health Acquisition	MaxHealth Acquisition On February 13, 2026, we acquired MaxHealth, a Florida-based primary care organization, for cash consideration of approximately $908 million, net of cash acquired. For additional information regarding acquisitions, refer to Note 3 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Revenue Recognition	Revenue Recognition Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that is recorded based upon established billing rates, less allowances for contractual adjustments, and is recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Reinsurance	Reinsurance During 2025 and 2026, we entered into agreements with unrelated insurers that do not qualify for reinsurance accounting under GAAP, and are accounted for using deposit accounting. These contracts minimize the risk of catastrophic loss, reducing capital and surplus requirements. Total deposit assets and liabilities related to these reinsurance agreements that do not qualify for reinsurance accounting under GAAP are not material at June 30, 2026.
Accounting Pronouncements Effective in Future Periods	Accounting Pronouncements Effective in Future Periods In November 2024, the FASB issued Accounting Standards Update No. 2024-03 — Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires significant additional disclosures disaggregating certain costs and expenses including purchases of inventory, employee compensation, depreciation, and intangible asset amortization. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2027 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our disclosures. In September 2025, The FASB issued Accounting Standards Update No. 2025-06 — Intangibles — Goodwill and Other — Internal Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The new guidance modernizes consideration of different methods of software development, updating the requirements for capitalization of software costs. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our interim 2028 financial statements, with early adoption permitted. We are currently evaluating the impact on our consolidated results of operations, financial position, and cash flows. There are no other recently issued accounting pronouncements that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

- Definition

Disclosure of accounting policy for business combination.

+ References

+ Details

FAIR VALUE - Schedule of Notional Amounts of Senior Notes Under Swap Agreements (Details) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	$ 7,250,000,000	$ 6,500,000,000
Interest Rate Swap Maturing 2031 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	700,000,000	700,000,000
Interest Rate Swap Maturing 2033 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	650,000,000	650,000,000
Interest Rate Swap Maturing 2034 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	800,000,000	800,000,000
Interest Rate Swap Maturing 2035 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	600,000,000	600,000,000
Interest Rate Swap Maturing 2038 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	200,000,000	0
Interest Rate Swap Maturing 2042 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	400,000,000	400,000,000
Interest Rate Swap Maturing 2044 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	750,000,000	600,000,000
Interest Rate Swap Maturing 2047 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	400,000,000	350,000,000
Interest Rate Swap Maturing 2049 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	500,000,000	450,000,000
Interest Rate Swap Maturing 2053 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	750,000,000	700,000,000
Interest Rate Swap Maturing 2054 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	1,000,000,000	800,000,000
Interest Rate Swap Maturing 2055 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, notional amount	500,000,000	$ 450,000,000
$1,500 million, 5.375% due April 15, 2031 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 1,500,000,000
Stated interest rate (as percent)	5.375%
$750 million, 5.875% due March 1, 2033 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	5.875%
$850 million, 5.950% due March 15, 2034 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 850,000,000
Stated interest rate (as percent)	5.95%
$750 million, 5.550% due May 1, 2035 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	5.55%
$250 million, 8.150% due June 15, 2038 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 250,000,000
Stated interest rate (as percent)	8.15%
$400 million, 4.625% due December 1, 2042 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 400,000,000
Stated interest rate (as percent)	4.625%
$750 million, 4.950% due October 1, 2044 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	4.95%
$400 million, 4.800% due March 15, 2047 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 400,000,000
Stated interest rate (as percent)	4.80%
$500 million, 3.950% due August 15, 2049 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (as percent)	3.95%
$750 million, 5.500% due March 15, 2053 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	5.50%
$1,000 million, 5.750% due April 15, 2054 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 1,000,000,000
Stated interest rate (as percent)	5.75%
$500 million, 6.000% due May 1, 2055 \| Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (as percent)	6.00%

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments (Details) $ in Millions	6 Months Ended
	Jun. 30, 2026 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 9,686
Acquisitions	831
Dispositions	(32)
Goodwill, ending balance	10,485
Insurance
Goodwill [Roll Forward]
Goodwill, beginning balance	2,663
Acquisitions	246
Dispositions	0
Goodwill, ending balance	2,909
CenterWell
Goodwill [Roll Forward]
Goodwill, beginning balance	7,023
Acquisitions	585
Dispositions	(32)
Goodwill, ending balance	$ 7,576

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

+ Details

COMMITMENTS, GUARANTEES AND CONTINGENCIES	6 Months Ended
COMMITMENTS, GUARANTEES AND CONTINGENCIES	Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS, GUARANTEES AND CONTINGENCIES	COMMITMENTS, GUARANTEES AND CONTINGENCIES Government Contracts Our Medicare products, which accounted for approximately 86% of our total premiums and services revenue for the six months ended June 30, 2026, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2026, and all of our product offerings filed with CMS and going to market for 2026 have been approved. CMS uses a risk-adjustment model that adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans. In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with payment year (PY) 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS. In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed (Proposed RADV Rule) applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.” We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (APA). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2027 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. CMS confirmed its intent to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without the use of a FFS Adjuster, when it selected certain of Humana's MA contracts for PY 2018 RADV audits. CMS has also initiated RADV audits for payment years 2019, 2020, and 2021, selecting certain of Humana's MA contracts for all audited years, announced it will follow a rolling schedule to initiate audits for subsequent payment years, and stated that the decision on whether it will apply extrapolation to the ongoing audits will be made at a later date. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, the expansion of CMS's auditing efforts to include all eligible MA contracts, the acceleration of RADV audits for PY 2018 through PY 2024, other changes CMS may make to the RADV audit methodology for these years, and combination of these expanded auditing efforts with the application of the Final RADV Rule, could each have a material adverse effect on our results of operations, financial position, or cash flows. On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. On September 25, 2025, the Court granted our motion for summary judgment and vacated the Final RADV Rule, finding that the Final RADV Rule was procedurally invalid under the APA because it was not a “logical outgrowth” of the Proposed RADV Rule. On November 21, 2025, the government notified the court of its appeal of that decision, which is now pending at the United States Court of Appeals for the Fifth Circuit and captioned Humana v Kennedy. There can be no assurances as to the final disposition of this lawsuit. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows. In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows. Our state-based Medicaid business, which accounted for approximately 8% of our total premiums and services revenue for the six months ended June 30, 2026 primarily serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states. The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows. Legal Proceedings and Certain Regulatory Matters From time to time, the Civil Division of the United States Department of Justice has provided us with information requests, concerning our Medicare Part C risk adjustment practices. These requests relate to our oversight and submission of risk adjustment data generated by providers, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by our Medicare Advantage Organizations. We continue to cooperate with the Department of Justice on these requests. On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. On September 25, 2025, the Court granted our motion for summary judgment and vacated the Final RADV Rule, finding that the Final RADV Rule was procedurally invalid under the APA because it was not a "logical outgrowth" of the Proposed RADV Rule. On November 21, 2025, the government notified the court of its appeal of that decision, which is now pending at the United States Court of Appeals for the Fifth Circuit and captioned Humana v Kennedy. There can be no assurances as to the final disposition of this lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter. In June 2024, a putative stockholder class action was filed against Humana Inc. and certain of our current and former executive officers under the federal securities laws in the United States District Court for the District of Delaware. The case, now captioned In re Humana Inc. Securities Litigation, alleges that between July 2022 and October 2024, Humana made false or misleading statements in its periodic SEC filings and statements to the financial markets about our financial performance and the medical costs, Star Ratings and certain distribution relationships with respect to our Medicare Advantage business. The action seeks, among other things, unspecified compensatory damages and attorneys' fees. Between July 2024 and March 2025, parallel stockholder derivative actions were filed in the United States District Court for the Western District of Kentucky, now consolidated and captioned In re Humana Shareholder Derivative Action, and Nicolaou v. Broussard, was filed in Commonwealth of Kentucky, Jefferson Circuit Court, alleging that the same claimed acts and omissions underlying the federal securities law case, as well as certain Medicare Advantage distribution relationships, also constitute a breach of fiduciary duty by certain of our current and former directors and executive officers. The actions seek, among other things, reforms to the Company's corporate governance and internal procedures, unspecified damages and attorneys' fees. We will vigorously defend against the allegations in all cases. On October 18, 2024, Humana Inc., along with co-plaintiff Americans for Beneficiary Choice, filed suit against the United States Department of Health and Human Services and its Secretary, Centers for Medicare and Medicaid Services, and its Administrator, in the United States District Court, Northern District of Texas, Fort Worth Division, seeking a determination that they violated the Administrative Procedure Act in administering the Medicare Advantage and Part D Star Ratings program. On October 14, 2025, the Court issued a decision rejecting our challenge to the 2025 Star Ratings. On November 25, 2025, we notified the court of our appeal, which is now pending in the United States Court of Appeals for the Fifth Circuit. There is no assurance that we will ultimately prevail in the lawsuit. For additional information on this matter, refer to Part I, Item 1A, "Risk Factors" in our 2025 Form 10-K, and Part II, Item 1A, "Risk Factors" of this Form 10-Q. On May 1, 2025, the Department of Justice (DOJ) filed a complaint in partial intervention related to a qui tam lawsuit filed by an individual formerly employed by eHealth, Inc., in the United States District Court for the District of Massachusetts. The intervened lawsuit is captioned United States of America ex. rel. Andrew Shea v. eHealth, Inc., et al., Case No. 1:21-cv-11777-DJC. The complaint alleges certain civil violations in connection with non-commission payments Humana made to three call center broker partners. The complaint also includes allegations relating to Humana’s marketing of Medicare Advantage plans to Medicare-eligible beneficiaries under the age of 65. The action seeks damages and penalties on behalf of the United States under the federal False Claims Act. The court ordered the qui tam action unsealed following the filing of DOJ’s complaint in partial intervention on May 1, 2025. We take seriously our obligations to comply with applicable regulatory requirements and laws, and will vigorously defend against these allegations. On December 30, 2025, the United States Court of Appeals for the Sixth Circuit denied Humana's petition for permission to appeal a district court order certifying a class in the action of David Elliott v Humana Inc., alleging violations of the Telephone Consumer Protection Act (TCPA), 47U.S.C. §227. The class action will proceed in the United States District Court, Western District of Kentucky. We take seriously our obligations to comply with TCPA and other consumer privacy requirements, and we will vigorously defend against these allegations. Other Lawsuits and Regulatory Matters Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider and vendor contracting and oversight, risk adjustment, competitive practices, commission payments, marketing payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices. We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, personal injury, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do. As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation. A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future. We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes. The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.

SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Schedule of Segment Results

Our segment results were as follows for the three and six months ended June 30, 2026 and 2025:



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended June 30, 2026	(in millions)
External revenues









Premiums revenue	$	38,834	$	—	$	—	$	38,834








Services revenue	199		1,581		—		1,780
Total external revenues	39,033		1,581		—		40,614



Intersegment revenues	2		5,209		(5,211)		—
Net investment income	105		—		148		253
Total revenues	39,140		6,790		(5,063)		40,867
Operating expenses:
Benefits	35,423		—		(53)		35,370
Operating costs	2,758		6,276		(5,056)		3,978

Depreciation and amortization	139		48		(28)		159
Total operating expenses	38,320		6,324		(5,137)		39,507
Income from operations	$	820	$	466	$	74	$	1,360



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended June 30, 2025	(in millions)
External revenues









Premiums revenue	$	30,716	$	—	$	—	$	30,716








Services revenue	206		1,194		—		1,400
Total external revenues	30,922		1,194		—		32,116



Intersegment revenues	1		4,343		(4,344)		—
Net investment income	171		—		101		272
Total revenues	31,094		5,537		(4,243)		32,388
Operating expenses:
Benefits	27,621		—		(56)		27,565
Operating costs	2,558		5,133		(4,144)		3,547

Depreciation and amortization	149		60		(31)		178
Total operating expenses	30,328		5,193		(4,231)		31,290
Income from operations	$	766	$	344	$	(12)	$	1,098



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Six months ended June 30, 2026	(in millions)
External revenues









Premiums revenue	$	76,543	$	—	$	—	$	76,543








Services revenue	446		3,009		2		3,457
Total external revenues	76,989		3,009		2		80,000



Intersegment revenues	3		9,881		(9,884)		—
Net investment income	207		—		308		515
Total revenues	77,199		12,890		(9,574)		80,515
Operating expenses:
Benefits	69,121		—		(44)		69,077
Operating costs	5,542		12,038		(9,578)		8,002

Depreciation and amortization	281		97		(56)		322
Total operating expenses	74,944		12,135		(9,678)		77,401
Income (loss) from operations	$	2,255	$	755	$	104	$	3,114



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Six months ended June 30, 2025	(in millions)
External Revenues









Premiums revenue	$	61,230	$	—	$	—	$	61,230






Services revenue	458		2,276		—		2,734
Total external revenues	61,688		2,276		—		63,964



Intersegment revenues	2		8,356		(8,358)		—
Net investment income	341		—		195		536
Total revenues	62,031		10,632		(8,163)		64,500
Operating expenses:
Benefits	54,296		—		(196)		54,100
Operating costs	5,092		9,777		(7,942)		6,927
Depreciation and amortization	303		119		(61)		361
Total operating expenses	59,691		9,896		(8,199)		61,388
Income from operations	$	2,340	$	736	$	36	$	3,112

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

FAIR VALUE

6 Months Ended

Jun. 30, 2026

Fair Value Disclosures [Abstract]

FAIR VALUE

Financial Assets

The following table summarizes our fair value measurements at June 30, 2026 and December 31, 2025, respectively, for financial assets measured at fair value on a recurring basis:


	Fair Value Measurements Using
	Fair Value		Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
	(in millions)
June 30, 2026
Cash equivalents	$	5,557	$	5,557	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	2,506		—		2,506		—
Mortgage-backed securities	4,034		—		4,034		—
Tax-exempt municipal securities	408		—		408		—
Mortgage-backed securities:
Residential	404		—		404		—
Commercial	1,084		—		1,068		16
Asset-backed securities	1,092		—		937		155
Corporate debt securities	8,100		—		7,804		296
Total debt securities	17,628		—		17,161		467
Securities lending invested collateral	702		702		—		—
Total invested assets	$	23,887	$	6,259	$	17,161	$	467

December 31, 2025
Cash equivalents	$	3,945	$	3,945	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	2,278		—		2,278		—
Mortgage-backed securities	3,651		—		3,651		—
Tax-exempt municipal securities	428		—		428		—
Mortgage-backed securities:
Residential	388		—		388		—
Commercial	1,012		—		996		16
Asset-backed securities	783		—		656		127
Corporate debt securities	7,656		—		7,359		297
Total debt securities	16,196		—		15,756		440
Securities lending invested collateral	638		638		—		—
Total invested assets	$	20,779	$	4,583	$	15,756	$	440

Our Level 3 assets had a fair value of $467 million, or 2.0% of total invested assets, and $440 million, or 2.1% of total invested assets, at June 30, 2026 and December 31, 2025, respectively. During the six months ended June

30, 2026 and 2025, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:


	For the six months ended June 30, 2026								For the six months ended June 30, 2025
	Mortgage-backed securities: Commercial		Asset-backed securities		Corporate debt securities		Total		Mortgage-backed securities: Commercial		Asset-backed securities		Corporate debt securities		Total
	(in millions)
Beginning balance at January 1	$	16	$	127	$	297	$	440	$	7	$	73	$	242	$	322
Total gains or losses:
Realized in earnings	—		—		(1)		(1)		—		—		—		—
Unrealized in other comprehensive income	—		(1)		(3)		(4)		—		—		3		3
Purchases	—		43		46		89		9		15		47		71
Maturities	—		—		(3)		(3)		—		—		(2)		(2)
Sales	—		—		(53)		(53)		—		—		—		—
Settlements	—		—		(1)		(1)		—		—		—		—
Transfers out	—		(14)		—		(14)		—		—		—		—
Transfers in	—		—		14		14		—		—		—		—
Balance at June 30	$	16	$	155	$	296	$	467	$	16	$	88	$	290	$	394

Interest Rate Swaps

We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on the Secured Overnight Financing Rate (SOFR), to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our condensed consolidated balance sheets at fair value as of the reporting date. Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy. The cumulative, aggregate decrease to the carrying value of the senior notes was approximately $129 million at June 30, 2026. Our swap positions at June 30, 2026 and December 31, 2025 included swap assets, included within other long-term assets on our condensed consolidated balance sheet, of $17 million and $57 million, respectively, and swap liabilities, included within other long-term liabilities on our condensed consolidated balance sheet, of $146 million and $51 million, respectively. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three and six months ended June 30, 2026 and 2025.

The following table summarizes the notional amounts at June 30, 2026 and December 31, 2025, respectively, for our senior notes under the swap agreements:


	Notional amount at
Senior Notes Under Swap Agreements	June 30, 2026		December 31, 2025
	(in millions)
$1,500 million, 5.375% due April 15, 2031	$	700	$	700
$750 million, 5.875% due March 1, 2033	650		650
$850 million, 5.950% due March 15, 2034	800		800
$750 million, 5.550% due May 1, 2035	600		600
$250 million, 8.150% due June 15, 2038	200		—
$400 million, 4.625% due December 1, 2042	400		400
$750 million, 4.950% due October 1, 2044	750		600
$400 million, 4.800% due March 15, 2047	400		350
$500 million, 3.950% due August 15, 2049	500		450
$750 million, 5.500% due March 15, 2053	750		700
$1,000 million, 5.750% due April 15, 2054	1,000		800
$500 million, 6.000% due May 1, 2055	500		450
Total Senior Notes Under Swap Agreements	$	7,250	$	6,500

Financial Liabilities

Our debt is recorded at carrying value in our condensed consolidated balance sheets. The carrying value of our junior subordinated and senior notes debt outstanding, net of unamortized debt issuance costs, was $12.9 billion at June 30, 2026 and $12.4 billion at December 31, 2025. The fair value of our junior subordinated and senior notes debt was $12.7 billion at June 30, 2026 and $12.2 billion at December 31, 2025. The fair value of our debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our commercial paper borrowings. The commercial paper borrowings were $1.3 billion at June 30, 2026. We had no outstanding commercial paper borrowings at December 31, 2025.

Put and Call Options Measured at Fair Value

The put and call options fair values associated with our primary care strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $1.6 billion and $20 million, respectively, at June 30, 2026. The put and call options fair values, derived from the Monte Carlo simulation, were $1.4 billion and $13 million, respectively, at December 31, 2025. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets. Fair value changes to the put and call options are included within Other expense, net within our condensed consolidated income statement.

Based on the updated revenue growth assumptions in our most recent projections, the first two cohorts of clinics under our partnership with WCAS can be called by us in 2026 for approximately $1.0 billion to $1.6 billion.

The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash

flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.


	June 30, 2026		December 31, 2025
Annualized volatility	21.6% - 22.6%		18.9% - 19.9%
Credit spread	0.6% - 1.5%		1.1% - 1.6%
Revenue exit multiple	1.5x - 2.5x		1.5x - 2.5x
Weighted average cost of capital	10.0% - 14.0%		10.5% - 14.5%
Long term growth rate	3.0	%	3.0	%

The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2026 and 2025, including the acquisition of MaxHealth in February 2026. The values of net tangible assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The majority of the related tangible assets acquired and liabilities assumed were recorded at their carrying value as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were internally estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. We developed internal estimates for expected cash flows and discount rates in the present value calculations. There were no material assets or liabilities measured at fair value on a nonrecurring basis during 2026 and 2025 other than the assets and liabilities assumed in these acquisitions and any subsequent impairments. We recorded an impairment charge of $128 million relating to our indefinite-lived intangible assets in 2025.

For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Jul. 28, 2026	Feb. 16, 2024	Feb. 15, 2024
Equity, Class of Treasury Stock [Line Items]
Cash dividend declared (in dollars per share)	$ 0.885
Stock repurchases		$ 100	$ 108	$ 109
Common shares acquired in connection with employee stock plans (in shares)			30	40
Common shares acquired in connection with employee stock plans, amount			$ 5	$ 9
2023 Share Repurchase Authorization
Equity, Class of Treasury Stock [Line Items]
Remaining authorized amount							$ 824
2024 Share Repurchase Authorization
Equity, Class of Treasury Stock [Line Items]
Share repurchase authorization						$ 3,000
Stock repurchases (in shares)			600	400
Stock repurchases			$ 103	$ 100
Stock repurchase average price (in dollars per share)			$ 182.13	$ 233.73
2024 Share Repurchase Authorization \| Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Remaining authorized amount					$ 2,700

DEBT - Schedule of Carrying Value of Debt Outstanding (Details) - USD ($)	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Short-term debt	$ 2,268,000,000		$ 0
Total long-term debt	11,979,000,000		12,369,000,000
Senior Notes
Debt Instrument [Line Items]
Total senior notes	949,000,000		0
$750 million, 1.350% due February 3, 2027 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (as percent)	1.35%	1.35%
Total senior notes	$ 520,000,000		0
Total long-term debt	0		563,000,000
$600 million, 3.950% due March 15, 2027 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 600,000,000	$ 600,000,000
Stated interest rate (as percent)	3.95%	3.95%
Total senior notes	$ 429,000,000
Total long-term debt	0		466,000,000
$500 million, 5.750% due March 1, 2028 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (as percent)	5.75%
Total long-term debt	$ 491,000,000		491,000,000
$500 million, 5.750% due December 1, 2028 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (as percent)	5.75%
Total long-term debt	$ 497,000,000		497,000,000
$750 million, 3.700% due March 23, 2029 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (as percent)	3.70%	3.70%
Total long-term debt	$ 526,000,000		586,000,000
$500 million, 3.125% due August 15, 2029 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000	$ 500,000,000
Stated interest rate (as percent)	3.125%	3.125%
Total long-term debt	$ 338,000,000		388,000,000
$500 million, 4.875% due April 1, 2030 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (as percent)	4.875%
Total long-term debt	$ 497,000,000		497,000,000
$1,500 million, 5.375% due April 15, 2031 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 1,500,000,000
Stated interest rate (as percent)	5.375%
Total long-term debt	$ 1,479,000,000		1,493,000,000
$750 million, 2.150% due February 3, 2032 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (as percent)	2.15%	2.15%
Total long-term debt	$ 485,000,000		592,000,000
$750 million, 5.875% due March 1, 2033 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	5.875%
Total long-term debt	$ 737,000,000		750,000,000
$850 million, 5.950% due March 15, 2034 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 850,000,000
Stated interest rate (as percent)	5.95%
Total long-term debt	$ 817,000,000		832,000,000
$750 million, 5.550% due May 1, 2035 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	5.55%
Total long-term debt	$ 735,000,000		746,000,000
$250 million, 8.150% due June 15, 2038 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 250,000,000
Stated interest rate (as percent)	8.15%
Total long-term debt	$ 258,000,000		260,000,000
$400 million, 4.625% due December 1, 2042 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 400,000,000
Stated interest rate (as percent)	4.625%
Total long-term debt	$ 368,000,000		374,000,000
$750 million, 4.950% due October 1, 2044 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	4.95%
Total long-term debt	$ 705,000,000		717,000,000
$400 million, 4.800% due March 15, 2047 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 400,000,000
Stated interest rate (as percent)	4.80%
Total long-term debt	$ 390,000,000		396,000,000
$500 million, 3.950% due August 15, 2049 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (as percent)	3.95%
Total long-term debt	$ 506,000,000		517,000,000
$750 million, 5.500% due March 15, 2053 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (as percent)	5.50%
Total long-term debt	$ 712,000,000		727,000,000
$1,000 million, 5.750% due April 15, 2054 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 1,000,000,000
Stated interest rate (as percent)	5.75%
Total long-term debt	$ 975,000,000		991,000,000
$500 million, 6.000% due May 1, 2055 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (as percent)	6.00%
Total long-term debt	$ 477,000,000		486,000,000
$1,000 million, 6.625% due September 15, 2056 \| Junior Subordinated Notes
Debt Instrument [Line Items]
Aggregate principal	$ 1,000,000,000	$ 1,000,000,000.0
Stated interest rate (as percent)	6.625%	6.625%
Total long-term debt	$ 986,000,000		0
Commercial paper
Debt Instrument [Line Items]
Commercial paper	$ 1,319,000,000		$ 0

DEBT - Junior Subordinated Notes (Details) - USD ($)	1 Months Ended	6 Months Ended
DEBT - Junior Subordinated Notes (Details) - USD ($)	Mar. 31, 2026	Jun. 30, 2026	Jun. 30, 2025
Line of Credit Facility [Line Items]
Proceeds from issuance of notes, net		$ 990,000,000	$ 1,481,000,000
$1,000 million, 6.625% due September 15, 2056 \| Junior Subordinated Notes
Line of Credit Facility [Line Items]
Aggregate principal	$ 1,000,000,000.0	$ 1,000,000,000
Stated interest rate (as percent)	6.625%	6.625%
Proceeds from issuance of notes, net	$ 990,000,000
Basis points spread on variable rate	2.891%
Debt instrument, payment deferral term	10 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 6,893	$ 4,200
Investment securities	16,978	15,703
Receivables, net of allowances of $117 in 2026 and $108 in 2025	5,695	3,270
Other current assets	10,520	9,560
Total current assets	40,086	32,733
Property and equipment, net	2,098	2,231
Long-term investment securities	650	493
Equity method investments	627	638
Goodwill	10,485	9,686
Other long-term assets	3,250	3,128
Total assets	57,196	48,909
Current liabilities:
Benefits payable	12,876	9,967
Trade accounts payable and accrued expenses	7,263	5,717
Book overdraft	351	306
Unearned revenues	249	356
Short-term debt	2,268	0
Total current liabilities	23,007	16,346
Long-term debt	11,979	12,369
Other long-term liabilities	2,933	2,457
Total liabilities	37,919	31,172
Commitments and Contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued	0	0
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,719,832 shares issued at June 30, 2026 and 198,719,321 shares issued at December 31, 2025	33	33
Capital in excess of par value	3,701	3,600
Retained earnings	30,741	29,075
Accumulated other comprehensive loss	(751)	(633)
Treasury stock, at cost, 78,639,524 shares at June 30, 2026 and 78,128,009 shares at December 31, 2025	(14,511)	(14,418)
Total stockholders' equity	19,213	17,657
Noncontrolling interests	64	80
Total equity	19,277	17,737
Total liabilities and equity	$ 57,196	$ 48,909

DEBT - Revolving Credit Agreements (Details) - USD ($)	1 Months Ended		6 Months Ended
DEBT - Revolving Credit Agreements (Details) - USD ($)	May 31, 2025	May 31, 2024	Jun. 30, 2026	Apr. 30, 2025
5-year unsecured revolving credit agreement May 2025 \| Loans Payable
Line of Credit Facility [Line Items]
Actual debt to capitalization (as percent)			42.70%
Revolving Credit Facility \| 5-year unsecured revolving credit agreement May 2025
Line of Credit Facility [Line Items]
Debt instrument term (in years)	5 years
Maximum borrowing capacity	$ 5,000,000,000.0
Basis points spread on variable rate			1.015%
Facility fee			0.11%
Maximum debt to capitalization (as percent)			60.00%
Uncommitted incremental loan facility			$ 1,000,000,000.0
Maximum borrowing capacity including uncommitted incremental loan facility			6,000,000,000.0
Remaining borrowing capacity			$ 5,000,000,000.0
Revolving Credit Facility \| 5-year unsecured revolving credit agreement May 2025 \| Minimum
Line of Credit Facility [Line Items]
Basis points spread on variable rate			0.795%
Facility fee			0.08%
Revolving Credit Facility \| 5-year unsecured revolving credit agreement May 2025 \| Maximum
Line of Credit Facility [Line Items]
Basis points spread on variable rate			1.30%
Facility fee			0.20%
Revolving Credit Facility \| 5-year unsecured revolving credit agreement June 2023
Line of Credit Facility [Line Items]
Maximum borrowing capacity				$ 2,642,000,000
Revolving Credit Facility \| 364-day unsecured revolving credit agreement May 2024
Line of Credit Facility [Line Items]
Debt instrument term (in years)		364 days
Maximum borrowing capacity		$ 2,100,000,000

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Services	Health Care [Member]	Health Care [Member]	Health Care [Member]	Health Care [Member]
Revenues:
Premiums	$ 38,834	$ 30,716	$ 76,543	$ 61,230
Services	1,780	1,400	3,457	2,734
Net investment income	253	272	515	536
Total revenues	40,867	32,388	80,515	64,500
Operating expenses:
Benefits	35,370	27,565	69,077	54,100
Operating costs	3,978	3,547	8,002	6,927
Depreciation and amortization	159	178	322	361
Total operating expenses	39,507	31,290	77,401	61,388
Income from operations	1,360	1,098	3,114	3,112
Interest expense	197	157	390	317
Other expense, net	211	200	177	363
Income before income taxes and equity in net losses	952	741	2,547	2,432
Provision for income taxes	238	179	633	585
Equity in net losses	(21)	(19)	(37)	(62)
Net income	693	543	1,877	1,785
Net loss attributable to noncontrolling interests	1	2	3	4
Net income attributable to Humana	$ 694	$ 545	$ 1,880	$ 1,789
Basic earnings per common share (in dollars per share)	$ 5.78	$ 4.52	$ 15.64	$ 14.83
Diluted earnings per common share (in dollars per share)	$ 5.73	$ 4.51	$ 15.55	$ 14.81

BENEFITS PAYABLE

6 Months Ended

Jun. 30, 2026

Insurance [Abstract]

BENEFITS PAYABLE

On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the six months ended June 30, 2026 and 2025:


	For the six months ended June 30,
	2026		2025
	(in millions)
Balances, beginning of period	$	9,967	$	10,440

Incurred related to:
Current year	69,519		54,738
Prior years	(442)		(638)
Total incurred	69,077		54,100
Paid related to:
Current year	(57,511)		(44,818)
Prior years	(8,657)		(8,662)
Total paid	(66,168)		(53,480)
Balances, end of period	$	12,876	$	11,060

The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the incurred claims amounts. At June 30, 2026 and June 30, 2025, benefits payable included IBNR of approximately $8.9 billion and $7.0 billion, primarily associated with claims incurred in each respective period.

Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).

Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

- Definition

The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References + Details

MEDICARE PART D	6 Months Ended
MEDICARE PART D	Jun. 30, 2026
Insurance [Abstract]
MEDICARE PART D	MEDICARE PART D We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at June 30, 2026 and December 31, 2025. CMS subsidies/discounts include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants funded by CMS and pharmaceutical manufacturers. The accompanying condensed consolidated balance sheets include $1.1 billion of net assets and $1.5 billion of net assets associated with subsidy programs at June 30, 2026 and December 31, 2025, respectively. The accompanying condensed consolidated balance sheets also include $1.4 billion of net assets and $1.6 billion of net assets associated with cost sharing programs at June 30, 2026 and December 31, 2025, respectively. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SEGMENT INFORMATION - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
SEGMENT INFORMATION - Narrative (Details) $ in Millions	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) segment	Jun. 30, 2025 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment			2
Member co-share amounts and government subsidies	$ 4,400	$ 3,300	$ 8,700	$ 6,500
Depreciation and amortization classified as benefit expense	$ 29	$ 32	$ 60	$ 65

INVESTMENT SECURITIES - Schedule of Contractual Maturities of Debt Securities Available for Sale (Details) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Amortized Cost
Due within one year	$ 1,134
Due after one year through five years	4,639
Due after five years through ten years	4,478
Due after ten years	1,254
Mortgage and asset-backed securities	7,096
Amortized Cost	18,601	$ 17,017
Fair Value
Due within one year	1,127
Due after one year through five years	4,497
Due after five years through ten years	4,335
Due after ten years	1,055
Mortgage and asset-backed securities	6,614
Fair Value	$ 17,628	$ 16,196

INVESTMENT SECURITIES - Schedule of Investment Securities Classified as Current and Long-Term (Details) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	$ 18,601	$ 17,017
Gross Unrealized Gains	16	46
Gross Unrealized Losses	(989)	(867)
Fair Value	17,628	16,196
U.S. Treasury and agency obligations
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	2,572	2,314
Gross Unrealized Gains	0	3
Gross Unrealized Losses	(66)	(39)
Fair Value	2,506	2,278
Mortgage-backed securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	4,407	3,980
Gross Unrealized Gains	3	7
Gross Unrealized Losses	(376)	(336)
Fair Value	4,034	3,651
Tax-exempt municipal securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	419	442
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(11)	(14)
Fair Value	408	428
Residential
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	451	434
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(47)	(46)
Fair Value	404	388
Commercial
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	1,131	1,058
Gross Unrealized Gains	1	1
Gross Unrealized Losses	(48)	(47)
Fair Value	1,084	1,012
Asset-backed securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	1,107	791
Gross Unrealized Gains	2	4
Gross Unrealized Losses	(17)	(12)
Fair Value	1,092	783
Corporate debt securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	8,514	7,998
Gross Unrealized Gains	10	31
Gross Unrealized Losses	(424)	(373)
Fair Value	$ 8,100	$ 7,656

COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details) - broker	6 Months Ended
	Jun. 30, 2026	May 01, 2025
eHealth Litigation
Loss Contingencies [Line Items]
Number of call center brokers for which non-commission payments were made		3
Medicare
Loss Contingencies [Line Items]
Total premiums and services revenue (as percent)	86.00%
Medicaid
Loss Contingencies [Line Items]
Total premiums and services revenue (as percent)	8.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482645/405-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.W.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

INVESTMENT SECURITIES

6 Months Ended

Jun. 30, 2026

Investments, Debt and Equity Securities [Abstract]

INVESTMENT SECURITIES

Investment securities classified as current and long-term were as follows at June 30, 2026 and December 31, 2025, respectively:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in millions)
June 30, 2026
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	2,572	$	—	$	(66)	$	2,506
Mortgage-backed securities	4,407		3		(376)		4,034
Tax-exempt municipal securities	419		—		(11)		408
Mortgage-backed securities:
Residential	451		—		(47)		404
Commercial	1,131		1		(48)		1,084
Asset-backed securities	1,107		2		(17)		1,092
Corporate debt securities	8,514		10		(424)		8,100
Total debt securities	$	18,601	$	16	$	(989)	$	17,628



December 31, 2025
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	2,314	$	3	$	(39)	$	2,278
Mortgage-backed securities	3,980		7		(336)		3,651
Tax-exempt municipal securities	442		—		(14)		428
Mortgage-backed securities:
Residential	434		—		(46)		388
Commercial	1,058		1		(47)		1,012
Asset-backed securities	791		4		(12)		783
Corporate debt securities	7,998		31		(373)		7,656
Total debt securities	$	17,017	$	46	$	(867)	$	16,196

During the quarter ended June 30, 2026, we disposed of our corporate debt securities of Gentiva Hospice and recognized an immaterial gain.

We participate in a securities lending program where we loan certain investment securities for short periods of time in exchange for collateral, consisting of cash or U.S. Government securities, initially equal to at least 102% of the fair value of the investment securities on loan. Collateral with a fair value of $702 million and $638 million was held at June 30, 2026 and December 31, 2025, respectively. At June 30, 2026 and December 31, 2025, collateral from lending our investment securities was reinvested in short-term, highly liquid assets. In addition, we participated in non-cash securities lending with a fair value of $176 million and $193 million at June 30, 2026 and December 31, 2025, respectively.


	Less than 12 months				12 months or more				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
	(in millions)
June 30, 2026
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	1,661	$	(29)	$	673	$	(37)	$	2,334	$	(66)
Mortgage-backed securities	1,746		(33)		1,907		(343)		3,653		(376)
Tax-exempt municipal securities	106		(1)		241		(10)		347		(11)
Mortgage-backed securities:
Residential	80		(1)		302		(46)		382		(47)
Commercial	301		(3)		685		(45)		986		(48)
Asset-backed securities	578		(4)		191		(13)		769		(17)
Corporate debt securities	3,522		(55)		3,371		(369)		6,893		(424)
Total debt securities	$	7,994	$	(126)	$	7,370	$	(863)	$	15,364	$	(989)

December 31, 2025
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	643	$	(7)	$	857	$	(32)	$	1,500	$	(39)
Mortgage-backed securities	593		(3)		2,373		(333)		2,966		(336)
Tax-exempt municipal securities	51		—		347		(14)		398		(14)
Mortgage-backed securities:
Residential	10		—		321		(46)		331		(46)
Commercial	77		—		794		(47)		871		(47)
Asset-backed securities	85		—		263		(12)		348		(12)
Corporate debt securities	872		(6)		3,785		(367)		4,657		(373)
Total debt securities	$	2,331	$	(16)	$	8,740	$	(851)	$	11,071	$	(867)

Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by Standard & Poor's Rating Service, or S&P, at June 30, 2026. Our remaining debt securities below investment-grade were primarily rated BB-. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.

Our unrealized losses from all debt securities were generated from approximately 2,075 positions out of a total of approximately 2,925 positions at June 30, 2026. All issuers of debt securities we own that were trading at an unrealized loss at June 30, 2026 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At June 30, 2026, we

did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three and six months ended June 30, 2026 or 2025.

The detail of gains (losses) related to investment securities and included within net investment income was as follows for the three and six months ended June 30, 2026 and 2025:


	Three months ended June 30,				Six months ended June 30,
	2026		2025		2026		2025
	(in millions)				(in millions)
Gross gains on investment securities	$	8	$	13	$	10	$	18
Gross losses on investment securities	(33)		(2)		(36)		(5)


Net recognized (losses) gains on investment securities	$	(25)	$	11	$	(26)	$	13


	Amortized Cost		Fair Value
	(in millions)
Due within one year	$	1,134	$	1,127
Due after one year through five years	4,639		4,497
Due after five years through ten years	4,478		4,335
Due after ten years	1,254		1,055
Mortgage and asset-backed securities	7,096		6,614
Total debt securities	$	18,601	$	17,628

For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash flows from operating activities
Net income	$ 693	$ 543	$ 1,877	$ 1,785
Adjustments to reconcile net income to net cash provided by operating activities:
Losses (gains) on investment securities, net	25	(11)	26	(13)
Equity in net losses	21	19	37	62
Stock-based compensation			116	110
Depreciation			363	396
Amortization			19	30
Impairment of property and equipment			25	14
Impairment of indefinite-lived intangible assets		32	0	32	$ 128
Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions:
Receivables			(2,392)	(1,800)
Other assets			(902)	(658)
Benefits payable			2,909	620
Other liabilities			1,241	1,010
Unearned revenues			(107)	14
Other, net			8	0
Net cash provided by operating activities			3,220	1,602
Cash flows from investing activities
Proceeds from sale of business, net			40	0
Acquisitions, net of cash acquired			(930)	(1)
Purchases of property and equipment, net			(253)	(209)
Purchases of investment securities			(4,230)	(1,941)
Proceeds from maturities of investment securities			1,561	1,617
Proceeds from sales of investment securities			1,050	1,243
Changes in securities lending collateral receivable			(64)	(48)
Net cash (used in) provided by investing activities			(2,826)	661
Cash flows from financing activities
Receipts (payments) from contract deposits, net			547	(579)
Proceeds from issuance of notes, net			990	1,481
Repayments of notes			(281)	(771)
Proceeds (repayments) from issuance of commercial paper, net			1,300	(5)
Debt issue costs			(16)	(5)
Change in book overdraft			45	(105)
Common stock repurchases			(108)	(109)
Dividends paid			(214)	(214)
Changes in securities lending payable			64	48
Changes in rebate factor payable			0	(123)
Other			(28)	(62)
Net cash provided by (used in) financing activities			2,299	(444)
Increase in cash and cash equivalents			2,693	1,819
Cash and cash equivalents at beginning of period			4,200	2,221	2,221
Cash and cash equivalents at end of period	$ 6,893	$ 4,040	6,893	4,040	$ 4,200
Supplemental cash flow disclosures:
Interest payments			314	293
Details of businesses acquired in purchase transactions:
Fair value of assets acquired, net of cash acquired			989	2
Less: Fair value of liabilities assumed			(59)	(1)
Cash paid for acquired businesses, net of cash acquired			$ 930	$ 1

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Millions	Total	Total Stockholders' Equity	Common Stock	Capital In Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2024			198,719
Beginning balance at Dec. 31, 2024	$ 16,445	$ 16,375	$ 33	$ 3,463	$ 28,317	$ (1,067)	$ (14,371)	$ 70
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,785	1,789			1,789			(4)
Distribution to noncontrolling interest holders, net	(5)							(5)
Other comprehensive (loss) income	284	284				284
Common stock repurchases	(109)	(109)					(109)
Dividends and dividend equivalents	(215)	(215)			(215)
Stock-based compensation	110	110		110
Restricted stock unit vesting	0			(16)			16
Ending balance (in shares) at Jun. 30, 2025			198,719
Ending balance at Jun. 30, 2025	18,295	18,234	$ 33	3,557	29,891	(783)	(14,464)	61
Beginning balance (in shares) at Mar. 31, 2025			198,719
Beginning balance at Mar. 31, 2025	17,819	17,751	$ 33	3,497	29,453	(868)	(14,364)	68
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	543	545			545			(2)
Distribution to noncontrolling interest holders, net	(5)							(5)
Other comprehensive (loss) income	85	85				85
Common stock repurchases	(100)	(100)					(100)
Dividends and dividend equivalents	(107)	(107)			(107)
Stock-based compensation	60	60		60
Ending balance (in shares) at Jun. 30, 2025			198,719
Ending balance at Jun. 30, 2025	18,295	18,234	$ 33	3,557	29,891	(783)	(14,464)	61
Beginning balance (in shares) at Dec. 31, 2025			198,719
Beginning balance at Dec. 31, 2025	17,737	17,657	$ 33	3,600	29,075	(633)	(14,418)	80
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,877	1,880			1,880			(3)
Distribution to noncontrolling interest holders, net	(13)							(13)
Other comprehensive (loss) income	(118)	(118)				(118)
Common stock repurchases	(108)	(108)					(108)
Dividends and dividend equivalents	(214)	(214)			(214)
Stock-based compensation	116	116		116
Restricted stock unit vesting (in shares)			1
Restricted stock unit vesting	0			(12)			12
Stock option exercises	0			(3)			3
Ending balance (in shares) at Jun. 30, 2026			198,720
Ending balance at Jun. 30, 2026	19,277	19,213	$ 33	3,701	30,741	(751)	(14,511)	64
Beginning balance (in shares) at Mar. 31, 2026			198,720
Beginning balance at Mar. 31, 2026	18,646	18,580	$ 33	3,641	30,153	(731)	(14,516)	66
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	693	694			694			(1)
Distribution to noncontrolling interest holders, net	(1)							(1)
Other comprehensive (loss) income	(20)	(20)				(20)
Dividends and dividend equivalents	(106)	(106)			(106)
Stock-based compensation	65	65		65
Restricted stock unit vesting	0			(2)			2
Stock option exercises	0			(3)			3
Ending balance (in shares) at Jun. 30, 2026			198,720
Ending balance at Jun. 30, 2026	$ 19,277	$ 19,213	$ 33	$ 3,701	$ 30,741	$ (751)	$ (14,511)	$ 64

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Receivables, net of allowances	$ 117	$ 108
Preferred stock, par (in dollars per share)	$ 1	$ 1
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par (in dollars per share)	$ 0.1667	$ 0.1667
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	198,719,832	198,719,321
Treasury stock, at cost (in shares)	78,639,524	78,128,009

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References + Details

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References + Details

EARNINGS PER COMMON SHARE COMPUTATION (Tables)

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Earnings Per Common Share

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and six months ended June 30, 2026 and 2025:


	Three months ended June 30,				Six months ended June 30,
	2026		2025		2026		2025
	(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders	$	694	$	545	$	1,880	$	1,789
Weighted average outstanding shares of common stock used to compute basic earnings per common share	120,066		120,539		120,199		120,602
Dilutive effect of:
Employee stock options	—		—		—		—
Restricted stock	1,069		206		694		192
Shares used to compute diluted earnings per common share	121,135		120,745		120,893		120,794
Basic earnings per common share	$	5.78	$	4.52	$	15.64	$	14.83
Diluted earnings per common share	$	5.73	$	4.51	$	15.55	$	14.81
Number of antidilutive stock options and restricted stock excluded from computation	716		791		1,519		1,299

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2026

Intangible Asset, Goodwill and Other [Abstract]

Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments

Changes in the carrying amount of goodwill for our reportable segments for the six months ended June 30, 2026 were as follows:


	Insurance		CenterWell		Total
	(in millions)
Balance at January 1, 2026	$	2,663	$	7,023	$	9,686
Acquisitions	246		585		831
Dispositions	—		(32)		(32)

Balance at June 30, 2026	$	2,909	$	7,576	$	10,485

Schedule of Finite-Lived Intangible Assets Included in Other Long-Term Assets


	Weighted Average Life	June 30, 2026						December 31, 2025
		Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	790	$	—	$	790	$	790	$	—	$	790
Medicare licenses	Indefinite	262		—		262		262		—		262
Customer contracts/relationships	8.5 years	788		702		86		732		692		40
Trade names and technology	5.6 years	115		102		13		104		97		7
Provider contracts	11.9 years	66		64		2		67		65		2
Noncompetes and other	8.2 years	89		62		27		85		58		27

Total other intangible assets	8.4 years	$	2,110	$	930	$	1,180	$	2,040	$	912	$	1,128

Schedule of Indefinite-Lived Intangible Assets Included in Other Long-Term Assets


	Weighted Average Life	June 30, 2026						December 31, 2025
		Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	790	$	—	$	790	$	790	$	—	$	790
Medicare licenses	Indefinite	262		—		262		262		—		262
Customer contracts/relationships	8.5 years	788		702		86		732		692		40
Trade names and technology	5.6 years	115		102		13		104		97		7
Provider contracts	11.9 years	66		64		2		67		65		2
Noncompetes and other	8.2 years	89		62		27		85		58		27

Total other intangible assets	8.4 years	$	2,110	$	930	$	1,180	$	2,040	$	912	$	1,128

Schedule of Estimate of Amortization Expense

The following table presents our estimate of amortization expense remaining for 2026 and each of the next five succeeding years at June 30, 2026:


	(in millions)
For the years ending December 31,
2026	$	17
2027	28
2028	18
2029	16
2030	16
2031	10

- Definition

Tabular disclosure of goodwill.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

INCOME TAXES	6 Months Ended
INCOME TAXES	Jun. 30, 2026
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The effective income tax rate was 25.6% and 24.7% for the three months ended June 30, 2026, and 2025, respectively, and 25.2% and 24.6% for the six months ended June 30, 2026 and 2025, respectively. The 2026 quarter and period effective income tax rate increase is primarily related to state taxes. For the six months ended June 30, 2026 and 2025, we paid income taxes net of refunds of $141 million and $29 million, respectively. For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

BENEFITS PAYABLE (Tables)

6 Months Ended

Jun. 30, 2026

Insurance [Abstract]

Schedule of Activity in Benefits Payable

On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the six months ended June 30, 2026 and 2025:


	For the six months ended June 30,
	2026		2025
	(in millions)
Balances, beginning of period	$	9,967	$	10,440

Incurred related to:
Current year	69,519		54,738
Prior years	(442)		(638)
Total incurred	69,077		54,100
Paid related to:
Current year	(57,511)		(44,818)
Prior years	(8,657)		(8,662)
Total paid	(66,168)		(53,480)
Balances, end of period	$	12,876	$	11,060

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Statement of Comprehensive Income [Abstract]
Net income attributable to Humana	$ 694	$ 545	$ 1,880	$ 1,789
Other comprehensive (loss) income:
Change in gross unrealized investment (losses) gains	(33)	117	(156)	375
Effect of income taxes	9	(27)	35	(85)
Total change in unrealized investment (losses) gains, net of tax	(24)	90	(121)	290
Reclassification adjustment for net realized gains (losses)	5	(5)	4	(7)
Effect of income taxes	(1)	0	(1)	1
Total reclassification adjustment, net of tax	4	(5)	3	(6)
Other comprehensive (loss) income, net of tax	(20)	85	(118)	284
Comprehensive income attributable to Humana	$ 674	$ 630	$ 1,762	$ 2,073

ACQUISITIONS AND DIVESTITURES (Details) - USD ($) $ in Millions		6 Months Ended
	Feb. 13, 2026	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Business Combination [Line Items]
Acquisitions, net of cash acquired		$ 930	$ 1
Goodwill		$ 10,485		$ 9,686
MaxHealth
Business Combination [Line Items]
Acquisitions, net of cash acquired	$ 908
Goodwill	800
Other intangible asset acquired	71
Net tangible assets acquired	$ 59
Intangible assets, weighted average useful life	6 years 10 months 24 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-47

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

DEBT - Senior Notes (Details) - USD ($)	Jun. 30, 2026	Mar. 31, 2026
Interest Rate Swap
Debt Instrument [Line Items]
Cumulative, aggregate decrease to the carrying value of senior note	$ 129,000,000
$750 million, 1.350% due February 3, 2027 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (as percent)	1.35%	1.35%
Debt instrument, repurchased face amount	$ 44,000,000
Debt instrument, repurchase amount	43,000,000
$600 million, 3.950% due March 15, 2027 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 600,000,000	$ 600,000,000
Stated interest rate (as percent)	3.95%	3.95%
Debt instrument, repurchased face amount	$ 37,000,000
Debt instrument, repurchase amount	37,000,000
$750 million, 3.700% due March 23, 2029 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (as percent)	3.70%	3.70%
Debt instrument, repurchased face amount	$ 61,000,000
Debt instrument, repurchase amount	59,000,000
$500 million, 3.125% due August 15, 2029 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000	$ 500,000,000
Stated interest rate (as percent)	3.125%	3.125%
Debt instrument, repurchased face amount	$ 50,000,000
Debt instrument, repurchase amount	48,000,000
$750 million, 2.150% due February 3, 2032 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (as percent)	2.15%	2.15%
Debt instrument, repurchased face amount	$ 108,000,000
Debt instrument, repurchase amount	$ 94,000,000

SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

SEGMENT INFORMATION

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. Our Chief Executive Officer, the Chief Operating Decision Maker, utilizes these segment groupings and results of each segment, measured by income (loss) from operations, to assess performance and allocate resources primarily during our annual budget process and periodic forecast updates.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our stand-alone prescription drug plans, or PDP, and contracts with various states to provide Medicaid, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits. In addition, our Insurance segment includes our Military services business as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Our CenterWell intersegment revenues includes the operations of CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell primary care clinics. In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers and our home solutions business, including fee-for-service and certain value-based arrangements with our health plans.

We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $4.4 billion and $3.3 billion for the three months ended June 30, 2026 and 2025, respectively. For the six months ended June 30, 2026 and 2025 these amounts were $8.7 billion and $6.5 billion, respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy solutions operations, are included with benefits expense. The amount of this expense was $29 million and $32 million for the three months ended June 30, 2026 and 2025, respectively, and $60 million and $65 million for the six months ended June 30, 2026 and 2025, respectively.

Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2025 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.

Our segment results were as follows for the three and six months ended June 30, 2026 and 2025:



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended June 30, 2026	(in millions)
External revenues









Premiums revenue	$	38,834	$	—	$	—	$	38,834








Services revenue	199		1,581		—		1,780
Total external revenues	39,033		1,581		—		40,614



Intersegment revenues	2		5,209		(5,211)		—
Net investment income	105		—		148		253
Total revenues	39,140		6,790		(5,063)		40,867
Operating expenses:
Benefits	35,423		—		(53)		35,370
Operating costs	2,758		6,276		(5,056)		3,978

Depreciation and amortization	139		48		(28)		159
Total operating expenses	38,320		6,324		(5,137)		39,507
Income from operations	$	820	$	466	$	74	$	1,360



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended June 30, 2025	(in millions)
External revenues









Premiums revenue	$	30,716	$	—	$	—	$	30,716








Services revenue	206		1,194		—		1,400
Total external revenues	30,922		1,194		—		32,116



Intersegment revenues	1		4,343		(4,344)		—
Net investment income	171		—		101		272
Total revenues	31,094		5,537		(4,243)		32,388
Operating expenses:
Benefits	27,621		—		(56)		27,565
Operating costs	2,558		5,133		(4,144)		3,547

Depreciation and amortization	149		60		(31)		178
Total operating expenses	30,328		5,193		(4,231)		31,290
Income from operations	$	766	$	344	$	(12)	$	1,098



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Six months ended June 30, 2026	(in millions)
External revenues









Premiums revenue	$	76,543	$	—	$	—	$	76,543








Services revenue	446		3,009		2		3,457
Total external revenues	76,989		3,009		2		80,000



Intersegment revenues	3		9,881		(9,884)		—
Net investment income	207		—		308		515
Total revenues	77,199		12,890		(9,574)		80,515
Operating expenses:
Benefits	69,121		—		(44)		69,077
Operating costs	5,542		12,038		(9,578)		8,002

Depreciation and amortization	281		97		(56)		322
Total operating expenses	74,944		12,135		(9,678)		77,401
Income (loss) from operations	$	2,255	$	755	$	104	$	3,114



	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Six months ended June 30, 2025	(in millions)
External Revenues









Premiums revenue	$	61,230	$	—	$	—	$	61,230






Services revenue	458		2,276		—		2,734
Total external revenues	61,688		2,276		—		63,964



Intersegment revenues	2		8,356		(8,358)		—
Net investment income	341		—		195		536
Total revenues	62,031		10,632		(8,163)		64,500
Operating expenses:
Benefits	54,296		—		(196)		54,100
Operating costs	5,092		9,777		(7,942)		6,927
Depreciation and amortization	303		119		(61)		361
Total operating expenses	59,691		9,896		(8,199)		61,388
Income from operations	$	2,340	$	736	$	36	$	3,112

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details